In our study, we investigated the expression of p21CIP1, H3K9Me3, and Lamin B1 using immunohistochemistry (IHC) to evaluate TIS induction in breast cancer patients who received NAC and developed partial or poor response to therapy. The gene discussed is CDKN1A; the disease is breast carcinoma.